Gene Based Treatment Strategies For Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$2,630,000.00
Summary
Diabetic retinopathy is the leading cause of blindness in the working population of developed countries and it is an increasing problem in the developing world. Present therapy involves extensive laser destruction of the light-detecting part of he retina. In addition, it is not only effective when administered at an appropriate stage in the disease process. Consequently, there is an urgent need for the development of better, prophylactic, easily administrable and cheaper therapies. This project ....Diabetic retinopathy is the leading cause of blindness in the working population of developed countries and it is an increasing problem in the developing world. Present therapy involves extensive laser destruction of the light-detecting part of he retina. In addition, it is not only effective when administered at an appropriate stage in the disease process. Consequently, there is an urgent need for the development of better, prophylactic, easily administrable and cheaper therapies. This project aims to develop a potentially permanent solution to alleviate diabetes-related blindness in the world. The project combines several very recent scientific advances into one strategy to combat diabetic retinopathy at a molecular level. Vision is our most important sensory organ that cannot be replaced. Thus, human trials can only be conducted following extensive animal safety and efficacy trials. To date the development of new therapies has been seriously hampered by the lack of appropriate, easy to reproduce animal models for different stages of diabetic retinopathy. In addition, it aims to identify new therapeutic agents from molecules that are naturally produced by the retina while fighting the disease. Finally, tested and evaluated in the animal models. The most successful therapeutic candidates will then be further developed for human trials.If successful, our approach will potentially have a major impact on the treatment of diabetic retinopathy and possibly on all diabetic vascular diseases. A single injection might only be necessary to prevent the development of diabetic retinopathy, which would represent a significant weapon in the management of patients. In addition, successful application of secretion gene therapy in the eye might open up the possibility to introduce the same concept for the treatment of larger organs undergoing microvascular changes as a result of diabetes.Read moreRead less
The Genetic Understanding Of Asbestos Related Disorders (GUARD)
Funder
National Health and Medical Research Council
Funding Amount
$566,008.00
Summary
This proposal is to build a new national biospeciman resource for mesothelioma research that will both underpin and enhance the national health and medical research effort in Australia by systematically enabling a world-class resource for genetic epidemiological research. The Genetic Understanding of Asbestos-Related Disorders (GUARD) project aims to establish a national facility that will enable new, large-scale DNA banking capacity for malignant mesothelioma (MM) and other asbestos-related dis ....This proposal is to build a new national biospeciman resource for mesothelioma research that will both underpin and enhance the national health and medical research effort in Australia by systematically enabling a world-class resource for genetic epidemiological research. The Genetic Understanding of Asbestos-Related Disorders (GUARD) project aims to establish a national facility that will enable new, large-scale DNA banking capacity for malignant mesothelioma (MM) and other asbestos-related diseases. The GUARD biospecimen resource and linked database will integrate the current WA population-based asbestos-exposed cohorts with case collections from across Australia. The GUARD project will undertake high-quality research aimed at discovering the genes and gene: environment interactions underlying susceptibility, progression and variable response to chemotherapy in mesothelioma, and will facilitate National collaboration and research in the areas of genetic epidemiology and pharmacogenomics. Progress towards the goals of the GUARD project holds the potential for enormous public health benefits; the incidence of malignant melanoma is increasing, due to the long delay between asbestos exposure and diagnosis. GUARD will ensure that Australian researchers have access to a large and well-managed biospecimen resource linked to excellent clinical data, and that Australia takes the lead role internationally in genetic research into mesothelioma. GUARD data will be critical for understanding the importance and functional roles of specific genes in the general Australian population, and their relationship to particular environmental factors. Understanding how causal factors act at a population level will be a critical step for the clinical utilization of new genomic knowledge and tools to improve clinical practice and public health.Read moreRead less